Reduced plasma orexin-A levels in patients with bipolar disorder
Shoko Tsuchimine,1 Kotaro Hattori,1 Miho Ota,1 Shinsuke Hidese,1 Toshiya Teraishi,1 Daimei Sasayama,1 Hiroaki Hori,1 Takamasa Noda,2 Sumiko Yoshida,2 Fuyuko Yoshida,1 Hiroshi Kunugi11Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiat...
Enregistré dans:
Auteurs principaux: | Tsuchimine S, Hattori K, Ota M, Hidese S, Teraishi T, Sasayama D, Hori H, Noda T, Yoshida S, Yoshida F, Kunugi H |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2019
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/6823340e0a4342fb8ccdaf4e55c9efe0 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
par: Borjanka Batinic, et autres
Publié: (2021) -
Comparing the Self- and External Assessment Versions of the HCL-33 as Screening Instruments for Bipolar Disorder in Older Depressed Patients
par: Xinqiao Zhang, et autres
Publié: (2021) -
When should a psychiatrist remember to test homocysteine levels? - a literature review
par: Nowak Katarzyna, et autres
Publié: (2021) -
Tumor cell apoptosis mediated by the orexins
par: A. S. Diatlova, et autres
Publié: (2021) -
Prevalence of Comorbid Anxiety Disorders and Their Associated Factors in Patients with Bipolar Disorder or Major Depressive Disorder
par: Inoue T, et autres
Publié: (2020)